Please login to the form below
Beneluxa
This page shows the latest Beneluxa news and features for those working in and with pharma, biotech and healthcare.
Who's calling the shots in European healthcare?
A European pricing debate. Another major development in the last few years has been the creation of multi-country procurement and price negotiation groups in Europe, most notably the Beneluxa consortium
Latest news
-
NICE and Canadian counterpart to offer joint advice service
Similar moves are being made elsewhere in Europe, including the Beneluxa initiative, which comprises of the Netherlands, Belgium, Luxembourg, Austria and Ireland all banding together to focus on evaluating high cost
-
How to pay for very high cost, curative drugs? ICER and NICE put their heads together
These include the Beneluxa initiative, currently including five countries, alongside a EU goal of harmonising HTA across member states via new legislation this year.
-
Beneluxa: the future of European market access?
This was second time lucky for Beneluxa – its first joint appraisal on Vertex’s Orkambi broke down without a market access agreement. ... So Beneluxa is their opportunity to make the first move.”. He says some industry reticence is notable.
-
Better together when buying medicines? Taking stock of the BeNeLuxA initiative
The BeNeLuxA initiative Set up in 2015, the BeNeLuxA initiative aims to deliver sustainable access to innovative therapies. ... Progress across the programme. Progress is being made by BeNeLuxA across its work programme.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
